To determine whether the functional advantages of autophagy disruption observed in patient-derived ascites would translate to effective tumor control in vivo, we treated OVCAR3 tumor-bearing mice with 4x106ATG5-knockout or AAVS1-knockout CAR-T cells (Figure 5A). This evidence concerns the gene PPP1R12C and neoplasm.